Emily L. Larson, Yusuf Ciftci, Reed T. Jenkins, Alice L. Zhou, Jessica M. Ruck, Benjamin Philosophe
{"title":"Outcomes of Liver Transplant for Hepatic Epithelioid Hemangioendothelioma","authors":"Emily L. Larson, Yusuf Ciftci, Reed T. Jenkins, Alice L. Zhou, Jessica M. Ruck, Benjamin Philosophe","doi":"10.1111/ctr.70087","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Hepatic epithelioid hemangioendothelioma (HEH) is a rare indication of liver transplant with limited evidence.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Adult recipients undergoing first-time liver-only transplant from 2002 to 2021 in the United States were identified using the UNOS/OPTN database. We compared post-transplant outcomes of recipients receiving liver transplant for HEH versus other diagnoses. Survival was visualized using Kaplan-Meier curves and compared using log-rank test and multivariable Cox regression. Propensity score matching for recipient age, sex, and MELD was performed, with baseline characteristics and survival compared between groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 111 558 liver transplant recipients identified, 121 (0.1%) underwent transplant for HEH. Donors to HEH recipients were more often living donors. Recipients with HEH were younger, more likely to be female, and had lower BMI. Recipients with HEH had higher albumin, lower bilirubin, lower INR, and lower serum creatinine, as well as lower MELD scores and rates of ascites and encephalopathy. Similar post-transplant survival was observed for recipients with HEH (16.6 [lower 95% CI 14.9] years) and non-HEH diagnoses (13.8 [95% CI 13.6–13.9] years, log-rank <i>p</i> = 0.28), even after adjusting for baseline donor and recipient characteristics (aHR 1.28 [95% CI 0.94–1.74], <i>p</i> = 0.12). The propensity score matched cohort also had similar post-LT survival.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This national study represents the largest known report on liver transplant for HEH. The survival of recipients with HEH was similar to other etiologies, supporting the use of liver transplantation (LT) in advanced HEH.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 2","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Hepatic epithelioid hemangioendothelioma (HEH) is a rare indication of liver transplant with limited evidence.
Methods
Adult recipients undergoing first-time liver-only transplant from 2002 to 2021 in the United States were identified using the UNOS/OPTN database. We compared post-transplant outcomes of recipients receiving liver transplant for HEH versus other diagnoses. Survival was visualized using Kaplan-Meier curves and compared using log-rank test and multivariable Cox regression. Propensity score matching for recipient age, sex, and MELD was performed, with baseline characteristics and survival compared between groups.
Results
Of 111 558 liver transplant recipients identified, 121 (0.1%) underwent transplant for HEH. Donors to HEH recipients were more often living donors. Recipients with HEH were younger, more likely to be female, and had lower BMI. Recipients with HEH had higher albumin, lower bilirubin, lower INR, and lower serum creatinine, as well as lower MELD scores and rates of ascites and encephalopathy. Similar post-transplant survival was observed for recipients with HEH (16.6 [lower 95% CI 14.9] years) and non-HEH diagnoses (13.8 [95% CI 13.6–13.9] years, log-rank p = 0.28), even after adjusting for baseline donor and recipient characteristics (aHR 1.28 [95% CI 0.94–1.74], p = 0.12). The propensity score matched cohort also had similar post-LT survival.
Conclusions
This national study represents the largest known report on liver transplant for HEH. The survival of recipients with HEH was similar to other etiologies, supporting the use of liver transplantation (LT) in advanced HEH.
肝上皮样血管内皮瘤(HEH)是一种罕见的肝移植指征,证据有限。方法:使用UNOS/OPTN数据库对2002年至2021年在美国接受首次纯肝移植的成人受者进行识别。我们比较了因HEH和其他诊断接受肝移植的受者移植后的结果。生存率采用Kaplan-Meier曲线可视化,采用log-rank检验和多变量Cox回归进行比较。对受者的年龄、性别和MELD进行倾向评分匹配,并比较两组之间的基线特征和生存率。结果:111558例肝移植受者中,121例(0.1%)因HEH接受了肝移植。HEH受者的供体通常是活体供体。患有HEH的患者更年轻,更有可能是女性,并且BMI较低。HEH患者有较高的白蛋白、较低的胆红素、较低的INR和较低的血清肌酐,以及较低的MELD评分和腹水和脑病的发生率。即使在调整了供体和受体的基线特征(aHR 1.28 [95% CI 0.94-1.74], p = 0.12)后,HEH受者(16.6[较低95% CI 14.9]年)和非HEH受者(13.8 [95% CI 13.6-13.9]年)的移植后生存率相似。倾向评分匹配的队列也有相似的肝移植后生存率。结论:这项全国性的研究是目前已知最大的HEH肝移植报告。HEH受者的生存与其他病因相似,支持肝移植(LT)在晚期HEH中的应用。
期刊介绍:
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.